The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10820 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial combination studies

Preclinical Antimalarial Combination Studies: The Case of M5717, a P. falciparum Elongation Factor 2 Inhibitor and Pyronaridine, a Hemozoin Formation Inhibitor

February 17, 2020 - 14:33 -- Open Access
Author(s): 
Rottmann M, Jonat B, Spangenberg T, et al.
Reference: 
Antimicrob Agents Chemother. 2020 Feb 10, pii: AAC.02181-19.

Antimalarial drug resistance in the Plasmodium falciparum parasite poses a constant challenge for drug development. To mitigate this risk, new antimalarial medicines should be developed as fixed-dose combinations. Assessing the pharmacodynamic interactions of potential antimalarial drug combination partners during early phases of development is essential in developing the targeted parasitological and clinical profile of the final drug product.

Subscribe to RSS - antimalarial combination studies